501,872 Shares in Becton, Dickinson and Company $BDX Acquired by Jupiter Topco LLC

Jupiter Topco LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 501,872 shares of the medical instruments supplier’s stock, valued at approximately $75,944,000. Jupiter Topco LLC owned 0.18% of Becton, Dickinson and Company at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BDX. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company in the 3rd quarter valued at about $25,000. SHP Wealth Management bought a new position in Becton, Dickinson and Company in the 4th quarter worth about $26,000. Meeder Asset Management Inc. increased its stake in shares of Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the period. Prosperity Bancshares Inc acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. Finally, Main Street Group LTD bought a new stake in Becton, Dickinson and Company during the 1st quarter valued at $29,000. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $188.11 on Friday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $193.07. The firm’s 50 day simple moving average is $165.23 and its 200-day simple moving average is $160.33. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The company has a market cap of $51.83 billion, a P/E ratio of 56.66, a price-to-earnings-growth ratio of 13.41 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the firm earned $3.68 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on BDX shares. UBS Group started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective on the stock. The Goldman Sachs Group dropped their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Piper Sandler raised their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $185.67.

Insiders Place Their Bets

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 11,869 shares of company stock worth $1,994,719. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.